Many statistical studies report p-values for inferential purposes. In several scenarios, the stochastic aspect of p-values is neglected, which may contribute to drawing wrong conclusions in real data experiments. The stochastic nature of p-values makes their use to examine the performance of given testing procedures or associations between investigated factors to be difficult. We turn our focus on the modern statistical literature to address the expected p-value (EPV) as a measure of the performance of decision-making rules. During the course of our study, we prove that the EPV can be considered in the context of receiver operating characteristic (ROC) curve analysis, a well-established biostatistical methodology. The ROC-based framework provides a new and efficient methodology for investigating and constructing statistical decision-making procedures, including: (1) evaluation and visualization of properties of the testing mechanisms, considering, e.g. partial EPVs; (2) developing optimal tests via the minimization of EPVs; (3) creation of novel methods for optimally combining multiple test statistics. We demonstrate that the proposed EPV-based approach allows us to maximize the integrated power of testing algorithms with respect to various significance levels. In an application, we use the proposed method to construct the optimal test and analyze a myocardial infarction disease dataset. We outline the usefulness of the ''EPV/ROC'' technique for evaluating different decision-making procedures, their constructions and properties with an eye towards practical applications.
study, consider evaluating associations between a disease, say D, and two biomarkers, say A and B. It is not uncommon for scientists to conclude that the association between D and A is stronger than that between D and B if the p-value regarding the association between A and D is smaller than that of the association between B and D. This example demonstrates the non-careful use of the p-value's concept, since perhaps data obtained in a different but relevant experiment might provide the contradicting conclusion simply due to the stochastic nature of the p-value. These types of issues have led several scientific journals to discourage the use of p-values, with some scientists and statisticians encouraging their abandonment. 3 For example, the editors of the journal entitled Basic and Applied Social Psychology announced that the journal would no longer publish papers containing p-valuesbased studies, since the statistics were too often used to support lower quality research. 4 The p-value is a function of the data and hence it is a random variable, which too has a probability distribution. The subtlety in terms of those that try to interpret the magnitude of the relative p-value is that the distribution of the p-value is conditional on either the null hypothesis being true or not. Under the null hypothesis, commonly, pvalues have a Uniform[0,1] distribution. However, if the null hypothesis is false p-values have a non-Uniform[0,1] distribution for which the shape of the distribution varies across several factors including sample size and the distance of the parameter of interest from the hypothesized value (null). Hence, for the same exact null and alternative values, the distribution of the p-value may be small or large simply as a function of the sample size (statistical power). In the era of ''big data,'' it would not be unusual to constantly find extremely small p-values simply as function a massively large sample size, but having nothing really to do with scientific question. Likewise a large observed p-value may simply be due to a very small sample size.
Statisticians have long recognized the deficiencies in terms of interpreting p-values relative to their stochastic nature and have tried to develop remedies to aid scientists in the interpretation of their data. For example, Lazzeroni et al. 5 developed prediction intervals for p-values in replication studies. This approach has certain critical points regarding the following problems: (1) in the frequentist context, it is uncommon to create confidence intervals of random variables; (2) under the null hypothesis p-values are distributed according to a Uniform[0,1] distribution, whereas in many scenarios, if we are sure the alternative hypothesis is in effect, the prediction interval for the p-value is not needed; (3) prediction intervals for p-values can be directly associated with those for corresponding test statistics values, linking to just rejection sets of the test procedures.
The stochastic aspect of the p-value has been well studied by Dempster and Schatzoff 6 and Schatzoff 7 who introduced the concept of the expected significance level. Sackrowitz and Samuel-Cahn 8 developed the approach further and renamed it as the expected p-value (EPV). The authors presented the great potential of using EPVs in various aspects of hypothesis testing.
Comparisons of different test procedures, e.g. a Wilcoxon rank-sum test versus Student's t-test, based on their statistical power are oftentimes problematic in terms of deeming one method being the preferred test over a range of scenarios. One reason for this issue to occur is that the comparison between two or more testing procedures is dependent upon the choice of a pre-specified significance level . One test procedure may be more or less powerful than the other one depending on the choice of . Alternatively, one can consider the EPV concept in order to compare test procedures. In this paper, we show that the EPV corresponds to the integrated power of a test via all possible values of 2 ð0, 1Þ. Thus, the performance of the test procedure can be evaluated globally using the EPV concept. Smaller values of EPV show better test qualities in a more universal fashion. This method is an alternative approach to the Neyman-Pearson concept of testing statistical hypotheses. In this paper, we present a framework for optimal decision making criteria based on the EPV. The famous Neyman-Pearson lemma 9 (also see Vexler et al. 10 for details) introduced us to the concept that a reasonable statistical testing procedure controls the Type I error rate at a pre-specified significance level, , in conjunction with maximizing the power in a uniform fashion. Thus, for different values of we may obtain different superior test procedures. On the other hand, the EPV-based approach allows us to compare between decision-making rules in a more objective manner. The global test performance of testing procedures can be measured by one number, the EPV, and hence tests can be more easily rank-ordered.
In this paper, we further advance the concept of the EPV. We prove that there is a strong association between the EPV concept and the well-known receiver operating characteristic (ROC) curve methodology. The ROC curve technique is a very common biostatistical tool for describing the accuracy of different biomarkers in terms of predicting or diagnosing diseases. The area under the ROC curve (AUC) is a global summary index for measuring the diagnostic ability of a biomarker or combination of biomarkers to predict or diagnose disease. [10] [11] [12] [13] [14] [15] It turns out that we can use well-established ROC curve and AUC methods to evaluate and visualize the properties of various decision-making procedures in the p-value based context. Further, we develop a partial expected p-value (pEPV) and introduce a novel method for visualizing the properties of statistical tests in an ROC curve framework. The 'ROC/EPV' framework is proposed to solve multiple testing problems (e.g. Dmitrienko et al. 16 ).
Various experiments require rigorous statistical analyses involving the evaluation of sets consisting of more than one hypothesis. For example, in a case-control study, investigators may have expression levels of several hundred biomarkers measured to discriminate cases (disease) from controls (healthy). One may be interested in considering the discriminability of individual or different subsets of the biomarkers. An interesting issue is how one might combine the test statistics for testing the discriminability of certain sets of biomarkers. In this case, we should take into account that biomarkers can be dependent as well as the fact that their values may be measured on different scales. One approach towards addressing the multiple testing problem is to use the classical Bonferroni method or Benjamini-Hochberg procedure (e.g. Benjamini and Hochberg 17 ) . In this paper, we propose a novel EPV method to combine different test statistics in the multiple testing framework. This approach is based on a principle of maximization of AUCs or partial AUCs. We show that in many scenarios, the proposed methods outperform both the classical Bonferroni and Benjamini-Hochberg approaches. The novel EPV-based technique can be used to estimate the confidence regions of a set of vector parameters based on the confidence intervals for each of the respective vector components. This paper has the following structure: In Section 2, we define the EPV in the context of the ROC curve analysis. In Section 3, we demonstrate the common multiple testing issues and the current state-of-the-art solutions. We then propose novel methods for multiple testing problems that are shown to be superior in many instances. In Section 4, we present several examples to illustrate the proposed method as applied to the multiple testing problem. In Section 5, we carry out a Monte Carlo simulation study to evaluate the EPVs and the powers of the proposed decision-making mechanisms as compared to the classical Bonferroni family-wise error rate and Benjamini-Hochberg false discovery rate (FDR) approaches. Section 6 focuses on a real data example from a biomarker study associated with myocardial infarction (MI) disease, which shows the practicality and adaptability of the new method. In Section 7, we present concluding remarks.
The EPV in the context of an ROC curve analysis
In this section, we present the following material: The formal definition of the EPV; an overview of ROC curves; and the association between the EPV and the AUC. We also provide a new quantity called the pEPV, which characterizes a property of decision-making procedures using the concept of partial AUCs.
The expected p-value
Let the random variable TðDÞ represent a test statistic depending on data D. Assume In this setting, in order to concentrate upon the main issues, we will only focus on tests of the form: the event TðDÞ 4 C rejects H 0 , where C is a prefixed test threshold. Thus, the p-value has the form 1 À F 0 ðTðDÞÞ. Sackrowitz and Samuel-Cahn 8 proved that the expected
where independent random variables T 0 and T A are distributed according to F 0 and F 1 , respectively. The simple example of the EPV is when T 0 $ Nð 1 ,
Þ. Then the EPV can be expressed as
where È is the cumulative standard normal distribution. Note that the formal notation (1) is similar to that of the area under ROC curve. In this context, one can reconsider the EPV in terms of the area under ROC curve. In the next section, we outline the basic concepts of the ROC curve analysis.
The ROC curve and AUC-based approach
In biomedical research, a biomarker is frequently defined as a distinctive biological or biologically derived indicator of disease. For example, the prostate-specific antigen (PSA) biomarker is applied to diagnose prostate cancer; cardiac imaging biomarkers may be used to diagnose heart disease; the hemoglobin A1c (HbA1c) biomarker is known to be useful for diagnosing diabetes. The ROC curve analysis is an efficient approach for evaluating the discriminability of biomarkers. An ROC curve of a biomarker is a plot of its sensitivity (true positive rate) versus 1 minus its specificity (false-positive rate). For excellent reviews of statistical methods involving ROC curves and their applications, we refer the reader to Zou et al., 11 Liu and Schisterman, 12 Pepe, 18 Zhou et al. 15 and Vexler et al. 10 The AUC is a popular measure of the performance of a biomarker, with larger value of the area indicating a more accurate discriminating ability of a given marker (e.g. Liu et al. 19 ; Vexler et al. 14 ). Bamber 20 proved that the AUC can be expressed in the form
where that correspond to biomarker's measurements from diseased (D) and nondiseased ( " D) subjects, respectively. Thus, the AUC mechanism provides a convenient way to compare diagnostic biomarkers because the ROC curve places measurements for each biomarker on the same scale where they can be individually evaluated for accuracy.
The partial area under the ROC curve (pAUC) is the area under a portion of the ROC curve, oftentimes defined as the area between two false positive rates (FPRs). For example, the pAUC with two fixed a priori values for FPRs t 0 and t 1 is
are the survival functions of the diseased and healthy group, respectively. To simplify this notation, we denote
The association between EPV-based characteristics and ROC curve methodology
The area under the ROC curve is 1ÀEPV, which can be shown by equations (1) and (2) . This connection between the EPV and the AUC induces new techniques for evaluating statistical test qualities via the well-established ROC curve methodology. Consider, for illustrative purposes, the following example related to applications of Student's and Welch's t-tests. The recent biostatistical literature has extensively discussed which test, Student's t-or Welch's t-test, to use in practical applications. The questions in this setting are: What is the risk of using Student t-test when variances of the two populations are different as well as what is a loss in power when using Welch's t-test when the variances of the two populations are equal? 21, 22 In order to apply the ROC curve analysis based on the EPV concept, we denote Student's t-test statistic as
and Welch's t-test statistic as
where " X is the sample mean based on the independent normally distributed data points X 1 , . . . , X n , " Y is the sample mean based on the independent normally distributed observations These graphs show that there are no significant differences between the relative curves. In the scenario n ¼ 10, Table 1 . Thus, if the Type I error rates of the tests are correctly controlled, there are no critical differences between Student's t-test and Welch's t-test.
In the next section, we define the pEPV concept using test-power aspects and the pAUC approach. 
The connection between EPV and power
The value of the 1ÀEPV can be expressed in the form of the statistical power of a test through integration uniformly over the significance level from 0 to 1; that is
The above expression of the EPV considers the weight of the significance level from 0 to 1. It may appear to suffer from the defect of assigning most of its weight to relatively uninteresting values of not typically used in practice, e.g. ! 0:1. Alternatively, we can focus on significance levels of in a specific interesting range by considering the pEPV, that is
at a fixed upper level U 1.
Remark. (3) and (4) show that for a uniformly most powerful test (e.g. the likelihood ratio test), the EPV and pEPV will be the minimum as compared to any other tests with the same H 0 vs. H 1 .
Multiple testing problems
In practice, biostatistical experiments can focus on several hypothesis tests. A current example is to test for differences in gene expression profiles between healthy and diseased populations across potentially thousands of tests. In the multiple testing task, the concept of the family-wise experimental error rate (controlling the FPR across all tests) or the FDR (a method to boost power by allowing a higher ''known'' proportion of falsediscoveries to be declared statistically significant) needs to be considered in conjunction with the per comparison FPR. Multiple testing schemes adjust statistical inferences in an experiment for multiplicity by considering control of the family-wise error rate or FDR at level a and therefore control the overall number of false-positive results depending upon the methodology. For an excellent review of statistical methods involving multiple testing problems, see Dmitrienko et al. 16 In this section, in the context of the union-intersection test problems, we outline the classical Bonferroni procedure and the Benjamini-Hochberg (BH) approach. The new proposed method for multiple hypothesis testing problems is presented via the ROC-based methodology for optimally combining biomarkers.
The union-intersection test
Oftentimes, multiple hypothesis testing problems are stated as union-intersection problems. 23 For example, assume m biomarkers are involved to test for their individual ability to diagnose a disease. Towards this end, biomarkers' measurements are obtained from case and control populations and used to conduct and record values of m test statistics B 1 , . . . , B m for the hypotheses H 01 , . . . , H 0m against the alternative hypotheses H 11 , . . . , H 1m , respectively. The next study aim can focus on the global hypothesis H 0 defined as the intersection of the hypotheses tested versus the union of the alternative hypotheses (H 1 ):
T m i¼1 H 0i vs:
Moreover, the objectives of the study can be related to a subset, say S, of the biomarkers that requires analyzing the hypothesis H S 0 :
T i2S H 0i vs:
To address this problem, correct decision-making algorithms based on B 1 , . . . , B m need to be applied.
In modern scientific experiments, many large-scale hypotheses testing problems involve thousands of hypotheses as a joint family of interest. For example, in a DNA microarray experiment one may be interested in comparing the expression levels of a large number of genes in diseased subjects versus those in healthy subjects. The main goal of the experiment is to find a small group of ''interesting'' genes among the numerous genes whose expression levels differ between the diseased group and healthy group.
It is clear that the setting considered above can be associated with a problem to estimate confidence regions of vector-parameters based on confidence interval estimates of their respective elements.
The Bonferroni and the BH procedures
Perhaps, the Bonferroni procedure is one of the most widely used methods for addressing multiple testing problems. To illustrate the Bonferroni procedure, let p i be the unadjusted p-value for testing the individual null hypotheses H 0i , i ¼ 1, . . . , m. Then each p i can be considered as a test statistic for the respective H 0i , i ¼ 1, . . . , m. Thus, we can develop a test statistic for H 0 :
T m i¼1 H 0i vs: H 1 : S m i¼1 H 1i by constructing a decision-making rule based on p 1 , . . . , p m with a Type I error rate . The random variables p 1 , . . . , p m are dependent in general. In this framework, the Bonferroni scheme rejects H 0 if the events fp i =mg are detected for all i 2 1, . . . , m f g . This procedure is a very general method, which does not require any distributional assumptions and has a computational ease. However, the procedure tends to be conservative if the number of hypotheses is large or the test statistics are strongly correlated.
Benjamini and Hochberg 17 introduced a novel Bonferroni-type multiple adjusting procedure, which controls the FDR for a fixed value q 2 ð0, 1Þ. We refer the reader to the multiple testing problems literature for details regarding the FDR definition and its interpretations. The BH procedure is based on p ð1Þ p ð2Þ Á Á Á p ðmÞ , the ordered p-values, where p ðiÞ corresponds to the hypothesis H 0ðiÞ . The procedure rejects all H 0ðiÞ , i ¼ 1, . . . , k, where k ¼ max k 2 1, . . . , m f g: p ðiÞ iq=n È É , controlling the FDR at q.
Combinations of biomarkers
When multiple biomarkers are available, it is of common interest to combine the biomarkers to improve the diagnostic accuracy of a clinical test. One approach for doing this is to maximize the AUC based on functional combinations of biomarker measurements. This idea is employed as a basis for developing a novel method for combining the test statistics with respect to minimization of the EPV. Let us assume that a number of K biomarkers are available and the random vector
represents the levels of the given biomarkers. The expression level of the biomarkers is denoted by X ¼ X 1 , . . . , X K ð Þ T for the disease group and the expression level of biomarkers is denoted by Y ¼ Y 1 , . . . , Y K ð Þ T for the healthy group, with corresponding density functions f ¼ f ðx 1 , . . . , x K Þ and g ¼ gð y 1 , . . . , y K Þ, respectively. According to the Neyman-Pearson lemma, when the density functions f and g can be correctly specified, the likelihood ratio function, LRðMÞ ¼ f ðMÞ=gðMÞ yields the AUC ¼ Pr LRðXÞ ! LRðYÞ È É that is larger than the AUCs of any other combination of the biomarkers. 18, 24 In practice, the density functions f and g are generally unknown. In this case, combining multiple biomarkers using linear functions 25 is very popular due to its simplicity and the acceptability to clinicians. 26 Linear combination of biomarkers may be written as l ðk; The best linear combination (BLC) maximizes the AUC using the coefficient
Assuming the biomarkers of the healthy group and disease group follow normal distributions, Su and Liu 25 derived the BLC that yields the largest AUC. If the normality assumption is not met, Pepe and Thompson 27 and Chen et al. 26 have proposed non-parametric solutions to estimate the BLC. For example, one can maximize the Mann-Whitney U-statistic, an empirical estimate of AUC, by considering each linear combination l ðk, MÞ, via the value of
where I is the indicator function, X i ¼ ðX 1i , . . . , X Ki Þ T and Y j ¼ ðX 1j , . . . , X Kj Þ T present observed biomarkers' measurements related to an individual i from the disease group and an individual j from the healthy group, i ¼ 1, . . . ,n 1 and j ¼ 1, . . . ,n 2 . Then the empirical best linear combination coefficient k e is k e ¼ arg max AUC e ðkÞ ¼ arg max
The link between the notation of the EPV (1) and that of the AUC (2) leads us to use the methods regarding the combinations of biomarkers for developing the new method for combining the test statistics while minimizing the EPV.
Combinations of test statistics minimizing the EPV
For simplicity, suppose that in a multiple test problem there are only two hypotheses H 01 and H 02 that need to be tested against the alternative hypotheses H 11 and H 12 . Assume that we are interested in the unionintersection problem H 0 : H 01 \ H 02 vs: H 1 : H 11 [ H 12 and then the statistics T i , i ¼ 1, 2, are used to test H 0i vs: H 1i , i ¼ 1, 2, respectively. Define two bivariate independent random variables T H 0 ¼ ðT
Then the likelihood ratio combination
that is the minimum of the EPVs for any other combinations of the test statistics, where f H 0 and f H 1 are the joint density functions of T H 0 and T H 1 , respectively. The linear combinations of the test statistics can be obtained in the form
and then the corresponding EPV is
Therefore, the BLC coefficient, 0 , satisfies
In this case, the test statistic l ð 0 ; T 1 , T 2 Þ is the resulting combination of the test statistics.
In the context mentioned above, regarding the pEPV, the linear combination of the test statistics is l ; T 1 , T 2 ð Þ¼T 1 þ T 2 and the BLC coefficient, 0 , has the form
where F T 
Examples
In this section, we illustrate the proposed methods developed above towards tackling several multiple testing problems. The examples with the BLC of test statistics based on minimizing the EPV will demonstrate that combining different multiple tests using the proposed method can be a routine task without relying on the specification of the theoretical joint distributions.
Example 1 (parametric case)
Let X 1 , X 2 , . . . , X n be a random sample of size n from a Nð, 2 Þ distribution. Consider the following hypotheses
The null hypothesis to be tested restricts the location and scale parameters, the two main parameters in the normal distribution. Assume that the values of the t-test statistic T 1 ¼ " X ffiffi ffi n p =s and the 2 -test statistic T 2 ¼ ðn À 1Þs 2 are available only, where " X and s 2 are the sample mean and the sample variance, respectively. Since the data points are normally distributed and then their sample mean is independent from the sample standard deviation, one can prove that the joint distributions of T 1 and T 2 corresponding to H 1 : ð ¼ 1 4 0 or 2 ¼ 2 1 6 ¼ 1Þ and H 0 have the forms shown in the online supplementary materials. Then the LR test statistic, LRðT 1 , T 2 Þ, is described in the online Appendix that also presents the formal notation of MLRðT 1 , T 2 Þ, an approximated LRðT 1 , T 2 Þ, corresponding to the case where 1 and 1 are assume to be unknown.
In the scenario of this example, regarding the BLC method, we can obtain the combined test statistic
Á can be derived using the convolution calculations, or it can be accurately Monte Carlo approximated.
Example 2 (non-parametric case)
Let X 1 , . . . , X n be a random sample of size n from a population with mean and median M, and, say, we are interested in H 0 : ¼ 0, M ¼ M 0 vs: H 1 : 4 0 or M 6 ¼ M 0 , where M 0 is a specified value. The null hypothesis is about the two popular central tendencies. In Section 5, we examine this example choosing M 0 ¼ 0 and 0.5. Assume that to test for ¼ 0, the t-test (T 1 ¼ " X ffiffi ffi n p =s) was conducted; and to test for M ¼ M 0 , the onesample sign test based on the sample median (T 2 based on Med ðXÞ) was performed.
Ferguson 28 derived the joint distribution of the sample mean and the sample median. See the online supplementary materials for details and definitions. We apply this result to obtain the large sample approximation to the likelihood ratio combination of the test statistics based on X 1 , . . . , X n with the density function f in the form
where In a similar manner to the test construction mentioned above, one can provide an approximation to the BLC of the test statistics. In this scenario, data-driven methods, e.g. the bootstrap methodology, can be used to approximate the coefficient 0 
In Sections 5 and 6, we present more details regarding these algorithms.
Example 3 (a goodness-of-fit problem)
Consider the following hypothesis
We can call this hypothesis a reinforced goodness-of-fit type statement, where the hypothesis emphasizes the location difference. To test ¼ 0, the two-sided jt-testj is used (T 1 ) and to test X is normally distributed the wellknown Shapiro-Wilk test is used (T 2 ).
In the context of the BLC of the test statistics, we can obtain the combined test statistic
To compute approximated values of 0 , we use the fact that the distribution of T Table 2 shows that the percentage of the 180 scenarios that the average power of the proposed methods is higher than that of both the Bonferroni and BH procedures.
For example, there are 88% of the 180 scenarios that the average MC power of the MLR is higher than both the Bonferroni and BH procedures; 98% of the 180 scenarios that the average MC power of the BLC obtained using known alternative parameters is higher than both the Bonferroni and BH; 85% of the 180 scenarios that the average MC power of the BLC based on estimated alternative parameters is higher than both Bonferroni and BH, etc. Table 3 shows that the percentage of the 180 scenarios that the Monte Carlo EPV of the proposed methods is lower than both the Bonferroni and BH.
For example, there are 80% of the 180 scenarios that the MC EPV of the MLR is lower than both the Bonferroni and BH procedures; 99% of the 180 scenarios that the EPV of the BLC with known alternative parameters is lower than both the classical procedures; 73% of the 180 scenarios that the EPV of the BLC with bootstrap method is lower than both the classical procedures.
Online supplementary Table S1 shows the MC EPVs of the proposed methods and the classical procedures under some of the simulation scenarios. Among all the considered scenarios, the BLC has more cases with smaller EPVs. To justify the conducted results, Online supplementary Table S2 presents the MC Type I error rates of the proposed methods, the Bonferroni and BH procedures at the significant level ¼ 0:05 under control. The MC Type I error rates are controlled well when the tests are implemented.
Example 2 (The non-parametric case)
Consider the statement of Section 4.2. In this example, we deal with median values of M 0 ¼ 0 and 0.5 under H 0 in settings of two different underlying distributions, the normal and the exponential distributions, respectively. Testing relative to M 0 ¼ 0 is in Example 2.1 and testing relative to M 0 ¼ 0:5 is in Example 2.2. Table 4 shows that the percentage of the 30 scenarios that the average MC power of the proposed methods is higher than that of both the Bonferroni and the BH procedures. For example, there are 96.67% of the scenarios that the average power of the MLR of the test statistics is higher than that of both the Bonferroni and BH procedures, etc. While obtaining the outputs to calculate Table 4 , we observed that the classical procedures can slightly outperform the proposed schemes in the scenarios based on relatively large samples (n ! 150) with the alternative parameter 1 ! 0:35. In these cases, the considered procedures provided the average MC power values ' 1. Perhaps, in this study, Monte Carlo errors of the numerical experiments can have critical roles when n ! 150 and 1 ! 0:35. Table 5 shows that the percentage of the 30 scenarios that the EPV of the proposed methods is lower than that of both Bonferroni and BH procedures. The table displays that 100% of the scenarios that the EPV of the MLR is lower than that of both Bonferroni and BH schemes; 86.67% of the 30 scenarios that the EPV of the BLC with the estimated alternative parameters is lower than that of both the Bonferroni and BH schemes, etc.
Online supplementary Table S3 presents the EPVs of the proposed methods and the classical procedures in the different simulation scenarios. Among all the simulation scenarios, the BLC estimated using the bootstrap tilting method more frequently registers the smaller EPVs. Online supplementary Table S4 shows the MC type I error rates of the proposed methods, the Bonferroni and BH procedures at the significant level ¼ 0:05. The results show that the Type I error rates for the proposed methods are well controlled.
Example 2.2
Under the exponential distribution, consider the following hypothesis
Under the null hypothesis, we considered the values of the random variable a À a with $ Expð1Þ and a ¼ ðlnð2Þ À 1Þ À1 =2. In this example, we set up 32 scenarios based on the sample sizes of 30, 50, 75, 100, 150, 200, 300 and 500. For the alternative parameters, we have the mean and median ð 1 , M 1 Þ of (0, 0.6), ð0:1, 0:5Þ, ð0:1, 0:6Þ and ð0:2, 0:5Þ. Table 6 displays that the percentage of the 32 scenarios that the average MC power of the proposed methods is higher than that of both the Bonferroni and BH procedures. Table 7 shows that in a large percentage of the 32 scenarios the EPV of the proposed methods is lower than that of both the Bonferroni and BH procedures.
Tables 6 and 7 demonstrate that the proposed methods have the better power and lower EPV than those of the Bonferroni and BH methods.
Online supplementary Table S5 shows the detailed EPV of the proposed methods and the classical procedures in the different simulation scenarios. Among all the simulation scenarios, the BLC estimated using the bootstrap tilting method has more cases with smaller EPVs. Online supplementary Table S6 reports that the corresponding Type I error rates are controlled well when the tests are implemented at the significant level ¼ 0:05.
Example 3
To test the reinforced goodness-of-fit test (Section 4.3), we choose the sample sizes of 30, 50, 75 and 100, and under the alternative hypothesis, we simulate data from t-distributions with df ¼ f2, 5, 25g and the mean 1 ¼ f0, 0:5g and data from Laplace distribution with mean 1 ¼ 0. Thus, 28 designs of the generated samples are stated. Table 8 shows that the percentage of the 28 scenarios that the average MC power of the proposed methods is higher than that of both the Bonferroni and BH procedures. There are 100% of the 28 scenarios that the average MC power of the BLC is higher than that of both the Bonferroni and BH procedures; 83.33% scenarios that the average power of the BLC approximated using the bootstrap method is higher than both Bonferroni and BH schemes, etc. In a similar manner to that of Table 8 , Table 9 presents the percentage of the 28 scenarios that the EPV of the proposed methods is lower than that of both the Bonferroni and BH procedures. Tables 8 and 9 demonstrate that the proposed methods outperform the classical algorithms, the Bonferroni, and BH techniques. Supporting this conclusion, online supplementary Table S7 shows the detailed EPVs of the proposed methods and the classical procedures under some of the simulation scenarios. Online supplementary Table S8 indicates that the Type I error rates of the considered tests are controlled well at the significant level ¼ 0:05.
Remark: The Monte Carlo powers at ¼ 0:05 of the considered tests were also compared in the context of Examples 5.1-5.3. In this aspect, we observed that in most of situations the proposed methods are superior to the classical procedures. For example, we provide Table 10 that corresponds to Example 5.3.
Real data example
Myocardial infarction (MI) is commonly caused by blood clots blocking the blood flow of the heart leading heart muscle injury. The heart disease is leading cause of death affecting about or higher than 20% of populations regardless of different ethnicities according to the Centers for Disease Control and Prevention (e.g. Schisterman et al. 29, 30 ). We illustrate the application of the proposed approach based on a sample from a study that evaluates biomarkers related to the MI. The study was focused on the residents of Erie and Niagara counties, 35-79 years of age. The New York State department of Motor Vehicles drivers' license rolls were used as the sampling frame for adults between the age of 35 and 65 years, while the elderly sample (age: 65-79) was randomly chosen from the Health Care Financing Administration database. We consider the biomarker ''highdensity lipoprotein (HDL)-cholesterol'' that is often used as a discriminant factor between individuals with and without MI disease (e.g. Schisterman et al. 29, 30 ). The HDL-cholesterol levels were examined from a 12-h fasting blood specimen for biochemical analysis at baseline. A total of 366 measurements of HDL biomarker were evaluated by the study. The sample of 105 biomarker values was collected on cases who survived on MI and the sample of 261 measurements on controls who had no previous MI. Note that oftentimes measurements related to biological processes follow a log-normal distribution (see for details Limpert 31 and Vexler et al., 10 pp. [13] [14] . Thus, we are interested in whether the HDL cholesterol of the control group, say X, has the same log-normal distribution as that of the case group, Y. Online supplementary Figure S1 depicts the histograms based on values of log X ð Þ and log Y ð Þ, respectively. Our hypothesis to test can be expressed as
To test for X $ Y, the Wilcoxon-test (T 1 ) was performed, and to test log X ð Þ $ N, the Shapiro-Wilk test (T 2 ) was used. To examine the proposed ''EPV/ROC'' technique, we apply the following algorithm: (1) since under the null hypothesis the distribution function of ðX, YÞ is specified, the mean and the variance of log X ð Þ, log Y ð Þ È É were estimated and then 100,000 random variables were generated from the corresponding log-normal distribution to Monte-Carlo-approximate the distribution of T 
Thus, we could compare the average power and the EPVs of the BLC of the test statistics and those of the Bonferroni and BH procedures. In cases with the power<0.05, we could associate with the Type I error rates. The algorithm mentioned above was repeatedly used employing randomly selected subsamples from the data of sizes 25, 50, 75, 100 from the case and control groups to evaluate robustness of the test procedures. Figures 2 and 3 depict the average result via 1000 repetitions at each fixed sample size, n, regarding the average power (we evaluated the powers at different significant levels of 0.005, 0.01, 0.025, 0.05, and 0.1 and average them) and the EPVs of the estimated BLC (called ''BOOT'' in legends used in Figures 2 and 3) , the Bonferroni and BH procedures plotted again the sample sizes.
Figures 2 and 3 demonstrate that the BLC has the higher power and lower EPVs than those of the Bonferroni and BH procedures. As the sample size increases, the changes of the power and EPV of the proposed method are smaller than those of the classical procedures. This implies that the proposed method has better characteristics compared with the classical schemes based on relatively small sample sizes, while the differences between the tests vanish when the sample size increases.
Note that it is reasonable to assume that consistent test procedures based on relatively large samples have the much of the same operating characteristics, e.g. power one tests. In this example, we observed that the decisionmaking schemes under consideration simultaneously offer to reject the null hypothesis, when more than n ¼ 100 data points were employed. 
Discussion
We have seen that the EPV is a very useful and succinct tool as a measurement of performances in decision-making mechanisms. We have proposed a novel methodology to analyze and visualize characteristics of tests procedures. To this end, the ''EPV/ROC'' concept has been introduced. This approach provides us new and efficient perspectives to develop and examine statistical decision-making policies, including those related to: the partial EPV considerations, associations between the EPV and the power of tests, visualization of testing mechanisms' properties; developments of optimal tests minimizing the EPVs and creations of new methods for optimally combining multiple test statistics. Many possible researches can be done based on the concept we introduced in this paper. For example, a large sample theory can be developed to evaluate the EPVs in several parametric and nonparametric scenarios; Bayesian type methods can be developed in order to evaluate test properties in the ''EPV/ROC'' frame. The proposed technique can be easily applied to obtain confidence region estimation of vector-parameters based on their elements' confidence interval estimates. These topics need further strong empirical and methodological investigations. In the context of the multiple testing problem, the Bonferroni method and the Benjamini-Hochberg procedure were applied in this paper for an illustrative purpose only. The bootstrap tools including the Bootstrap tiling have been shown to be very reasonable in the test properties evaluations. We hope that the proposed concept convinces the medical practitioners regarding the usefulness of ''EPV/ ROC'' methodology to evaluate different decision-making procedures, their constructions and properties.
